MA(Medical Affairs) ÆòÆÇ(¹Ì±¹) - µ¿¸Æ°æÈ­¼º ½ÉÇ÷°üÁúȯ
Medical Affairs Reputations (US) - Atherosclerotic Cardiovascular Disease
»óǰÄÚµå : 1798376
¸®¼­Ä¡»ç : FirstWord Group
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 8,000 £Ü 11,260,000
Multi User License (PDF) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. PDF ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¹Ì±¹ ½ÉÀ庴 Àü¹®ÀǵéÀ» ´ë»óÀ¸·Î ÇÑ ÃֽŠÁ¶»ç¿¡ µû¸£¸é ÀϺΠÀ¯¸í ºê·£µåÀÇ µ¿¸Æ°æÈ­¼º ½ÉÇ÷°üÁúȯ MA(Medical Affairs) ÆÀÀÇ ¼º°ú´Â ¸î °¡Áö Áß¿äÇÑ ºÐ¾ß¿¡¼­ ¾ÆÁ÷ ¹ÌÈíÇÑ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. Àǻ簡 ÀßÇϰí ÀÖ´Ù°í »ý°¢ÇÏ´Â °Í, ´õ ÇØÁáÀ¸¸é ÇÏ´Â °Í, ºÒ¸¸Á·½º·¯¿î ÀÌÀ¯¸¦ ¹àÈü´Ï´Ù. À̹ø º¸°í¼­¿¡¼­´Â µ¿¸Æ°æÈ­¼º ½ÉÇ÷°üÁúȯÀ» Ä¡·áÇÏ´Â ÀÇ»çµéÀÇ ³ôÀº ±â´ë¿¡ MA(Medical Affairs)°¡ ¾î¶»°Ô ºÎÀÀÇÒ ¼ö ÀÖ´ÂÁö¿¡ ´ëÇØ ¾Ë¾Æº¾´Ï´Ù. ´Ù¾çÇÑ ±â¾÷ÀÇ ÁÖ¿ä µ¿¸Æ°æÈ­¼º ½ÉÇ÷°üÁúȯ Ä¡·á¿¡¼­ MA(Medical Affairs) ÆÀÀÇ ÇöÀç ¼º°ú¸¦ ºñ±³Çϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä Áú¹®

ÁÖ¿ä ºê·£µå

  • Leqvio
  • Praluent
  • Repatha
  • Tryngolza apabetalone
  • AZD0780
  • enlicitide
  • lepodisiran
  • obicetrapib
  • olpasiran
  • pelacarsen
  • ziltivekimab

Á¶»ç ¹æ¹ý

FirstView º¸°í¼­´Â 300¸¸ ¸í ÀÌ»óÀÇ Àǻ簡 È®ÀÎµÈ ¼¼°è ÃÖ´ë ÀÇ»ç µð·ºÅ丮ÀÎ LiMATMÀ» ÅëÇØ ¼±º°µÈ ÀÇ»çµéÀ» ´ë»óÀ¸·Î ½Ç½ÃÇÑ Á¤·®Àû ¼³¹®Á¶»ç¸¦ ÅëÇØ °³¹ßµÇ¾ú½À´Ï´Ù. °¢ ÀÇ»ç´Â ¾ö°ÝÇÑ ½É»ç ±âÁØ¿¡ µû¶ó ½ÅÁßÇÏ°Ô ¼±Á¤µÇ¾î ¼öÁýµÈ ÀλçÀÌÆ®ÀÌ ÀûÀýÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖÀ¸¸ç ÀÏ·ù ÀÇ·á Àü¹®°¡ÀÇ ÁøÁ¤ÇÑ °¨Á¤°ú °æÇèÀ» ¹Ý¿µÇÒ ¼ö ÀÖµµ·Ï º¸ÀåÇÕ´Ï´Ù. Á¶»ç °á°ú´Â ÇØ¼®Çϱ⠽¬¿î ±×·¡ÇÁ·Î Ç¥½ÃµÇ¾î µ¥ÀÌÅ͸¦ ºü¸£°Ô ÆÄ¾ÇÇÏ°í ºÐ¼®ÇÒ ¼ö ÀÖ½À´Ï´Ù. FirstView º¸°í¼­´Â LiMATMÀÇ ¹æ´ëÇÑ µµ´Þ ¹üÀ§¿Í Á¤È®¼ºÀ» Ȱ¿ëÇÏ¿© Àü·«Àû °èȹ ¼ö¸³À» À§ÇÑ Å¹¿ùÇÑ µ¥ÀÌÅÍ ±â¹Ý ÀλçÀÌÆ®¸¦ Á¦°øÇÔÀ¸·Î½á ºü¸£°Ô º¯È­ÇÏ´Â ÇコÄɾî ȯ°æ¿¡¼­ ÇÑ ¹ß ¾Õ¼­ ³ª°¥ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

´ç»ç º¸°í¼­ÀÇ Æ¯Â¡

FirstWord Reports´Â Á¦¾à ºÎ¹®¿¡ ƯȭµÈ ½Å·ÚÇÒ ¼ö ÀÖ´Â ¾÷°è ¸®´õ·Î¼­ ¹ÙÀÌ¿À Á¦¾à Àü¹®°¡¿Í ÀÇ»ç°áÁ¤±ÇÀÚ¸¦ À§ÇÑ »ó¼¼ÇÏ°í ½Ç¿ëÀûÀÎ ÀλçÀÌÆ®¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ´ç»çÀÇ ½ÉÃþÀûÀÎ ¾÷°è Áö½ÄÀº °í°´ÀÌ »õ·Î¿î Æ®·»µå¸¦ ÆÄ¾ÇÇÏ°í º¹ÀâÇÑ ¹®Á¦¸¦ È¿°úÀûÀ¸·Î ÇØ°áÇÒ ¼ö ÀÖµµ·Ï ÀûÀýÇÏ°í °¡Ä¡ ÀÖ´Â ÀλçÀÌÆ®¸¦ Á¦°øÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ±¤¹üÀ§ÇÑ Á¶»ç¿Í ÃÖ°í ¼öÁØÀÇ Àü¹®°¡ ¹× KOLÀÇ µ¶¸³ÀûÀÌ°í °øÁ¤ÇÑ ÀλçÀÌÆ®¸¦ ¹ÙÅÁÀ¸·Î ÇÑ ´ç»çÀÇ º¸°í¼­´Â °í°´ÀÌ ÇÊ¿ä·Î ÇÏ´Â Á¤È®¼º°ú ½Å·Ú¼ºÀ» Á¦°øÇÕ´Ï´Ù. ´Ù¸¥ °÷¿¡¼­´Â ¾òÀ» ¼ö ¾ø´Â ÀÎÅͺä¿Í µ¥ÀÌÅÍ¿¡ ´ëÇÑ µ¶Á¡Àû Á¢±Ù, Áö¼ÓÀûÀÎ ½ÃÀå ¸ð´ÏÅ͸µÀ» ÅëÇØ ½ÃÀå ¿ªÇÐÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. 40°³ ÀÌ»óÀÇ ¿ªµ¿ÀûÀÎ Áúȯ ¿µ¿ªÀ» ´Ù·ç°í, KOL ÀλçÀÌÆ®¿Í Á¤·®Àû ÀÇ»ç Á¶»ç¸¦ Æ÷ÇÔÇÑ ÀÇ»ç ÀÎÅÚ¸®Àü½º, ±×¸®°í ÀÇ·á ¹®Á¦, µðÁöÅÐ Çコ, ¿µ¾÷ ¹× ¸¶ÄÉÆÃ, ½ÃÀå Á¢±Ù ¹× ±âŸ ºÐ¾ßÀÇ À̽´¿¡ ´ëÇÑ ¾÷°è Àü¹®°¡µéÀÇ °ßÇØ¸¦ Á¦°øÇÏ´Â ´ç»çÀÇ º¸°í¼­´Â º¸´Ù ½º¸¶Æ®ÇÏ°í µ¥ÀÌÅÍ ±â¹ÝÀÇ ÀÇ»ç°áÁ¤À» ³»¸®°í ±Þº¯ÇÏ´Â ¾÷°è¿¡¼­ °æÀï·ÂÀ» À¯ÁöÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

According to this latest survey of US cardiologists, the performance of Atherosclerotic Cardiovascular Disease medical affairs teams for some high profile brands still has a way to go in some key areas. Find out what physicians think is done well; what they want to see more of; and why some are dissatisfied. This report reveals how medical affairs can better meet the high expectations of physicians treating Atherosclerotic Cardiovascular Disease. It compares the current performance of medical affairs teams for several leading treatments for Atherosclerotic Cardiovascular Disease from various companies.

Key Questions Answered:

Key Brands:

  • Leqvio
  • Praluent
  • Repatha
  • Tryngolza apabetalone
  • AZD0780
  • enlicitide
  • lepodisiran
  • obicetrapib
  • olpasiran
  • pelacarsen
  • ziltivekimab

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â